Pregnancy Clinical Trial
Official title:
Maternal Antibody in Milk After Vaccination
Single-centre observational pilot study exploring pertussis specific antibody concentration in the breastmilk of women vaccinated against pertussis in pregnancy at different gestational ages. This study is made up of two stages: first stage to confirm recruitment methods and optimise the laboratory assay and a second stage to complete recruitment for the pilot study.
Pertussis disease is a highly infectious respiratory illness caused by Bordetella pertussis,
which can cause significant morbidity and mortality. There has been an increase in cases in
many high income countries with high vaccination coverage and in an attempt to control this,
antenatal vaccination programmes have been introduced in several countries, including the UK.
Vaccination in pregnancy is a strategy which seeks to boost the maternal antibody levels,
increase the placental transfer of antibody and consequently increase the antibody levels in
the infant.
Human breast milk is a dynamic source of nutrition for the infant and is made up of many
immunologically active components including antibody. The principal antibody in breastmilk is
IgA and it has been shown that the amount of disease specific antibody in breastmilk can be
increased by vaccination in pregnancy for a number of pathogens including pertussis.
Secretory IgA (sIgA) plays an important role in immune exclusion in which it blocks adhesion
of a pathogen onto a mucosal surface. As the first step of pertussis pathogenesis is the
adhesion of bacteria to the ciliated respiratory epithelium in the nasopharynx and trachea
there is a clear biological rationale for the hypothesis that receiving breast milk
containing more IgA could enhance neonatal immunity and consequently the protective effects
of vaccination in pregnancy.
The best time in pregnancy for administering the pertussis vaccination is debated in the
literature, with some advocating vaccination in the second trimester and others supporting
later vaccination to coincide the time of serum antibody peak with optimum placental
transfer. This issue has been considered exclusively from the perspective of serum
immunoglobulin G (IgG), but the impact of timing of vaccination in pregnancy on IgA levels in
milk may also be important. Previous studies have shown that there is a peak in the pertussis
specific IgA in breast milk at day 10 following vaccination, which then declines, and
consequently there may be a significant difference in the amount of IgA available in the
breastmilk for an infant born to a mother vaccinated at 20 weeks for example, compared to a
mother vaccinated at 32 weeks. This may therefore have an impact on future guidelines on
optimal time of vaccination in pregnancy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
| Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
| Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
| Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
| Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
| Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
| Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
| Active, not recruiting |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
| Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
| Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
| Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
| Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
| Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
| Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
| Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
| Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
| Completed |
NCT02408315 -
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
|
Phase 3 |